Invex Therapeutics Ltd. (AU:IXC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invex Therapeutics Ltd has announced the retirement of Dr. Megan Baldwin as a Non-executive director, effective 30 June 2024. Baldwin, who joined the biopharmaceutical company in February 2021, played a pivotal role in advancing their leading drug, Exenatide, from Phase II to Phase III clinical trials for treating neurological conditions related to increased intracranial pressure. The company expressed gratitude for her significant contributions and wished her well in future endeavors.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.